Phase I evaluation of anguidine (diacetoxyscirpenol, NSC-141537)
- 1 July 1978
Abstract
A toxicologic evaluation of anguidine (diacetoxyscirpenol) was completed for a 5 day schedule. At 4.5 mg/M2 and 6 mg/M2 iv push CNS symptoms and hypotension were dose limiting but only mild to moderate myelosuppression was observed. At the 6 mg/M2 dose level on a 5 day schedule given by 8 hour infusion, myelosuppression was unacceptable while other toxic manifestations were minimal. An infusion of 4.5 mg/M2 over 4–8 hours appears to be an acceptable compromise between CNS, cardiovascular, and GI toxicity and myelosuppression. For patients with liver dysfunction or prior nitrosourea therapy, the starting dose should be 3.0 mg/M2.This publication has 4 references indexed in Scilit:
- Mechanism of inhibition of protein synthesis initiation by diacetoxyscirpenol and fusarenon X in the reticulocyte lysate systemBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1975
- Polyribosomal breakdown in mouse fibroblasts (L-cells) by fusarenox-X, a toxic principle isolated from Fusarium nivaleBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1972
- Toxicological research on substances from
- Phytotoxic Compounds produced byFusarium equisetiJournal of Experimental Botany, 1961